Ziarco

Ziarco is a clinical stage biotechnology company developing products to treat chronic inflammatory diseases with a focus on inflammatory skin disorders, in particular atopic dermatitis and psoriasis.On the 20 January 2017, Ziarco became a wholly owned subsidiary of Novartis.